メニューにジャンプコンテンツにジャンプ

トップページ > データサイエンス部 > 研究実績 > 2020年 研究業績

2020年 研究業績

  1. Uemura Y, Sone T, Tanaka S, Miyazaki T, Tsukiyama M, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M; Adequate Treatment of Osteoporosis (A-TOP) Research Group. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. Curr Med Res Opin, 36(11):1847-1859, 2020.
  2. Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y, Mukai H; RESPECT study group. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. J Clin Oncol, 38(32):3743-3752, 2020.
  3. Iwamoto T, Hara F, Uemura Y, Mukai H, Watanabe T, Ohashi Y. NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy. Breast Cancer Res Treat. 182(2):325-332, 2020.
  4. Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, Akabane H, Nishimura R, Takashima T, Park Y, Sagara Y, Toyama T, Imoto S, Mizuno T, Yamashita S, Fujii S, Uemura Y. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. Br J Cancer, 122(12):1747-1753, 2020.
  5. Taguchi S, Uemura Y, Fujimura T, Morikawa T, Naito A, Kawai T, Suzuki M, Kume H, Fukuhara H. Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model. BMC Cancer. 20(1):371, 2020.
  6. Matsuda W, Uemura T, Yamamoto M, Uemura Y, Kimura A. Impact of frailty on protocol-based weaning from mechanical ventilation in patients with sepsis: a retrospective cohort study. Acute Med Surg. 7(1):e608, 2020.
  7. Terada-Hirashima J, Suzuki M, Uemura Y, Hojo M, Mikami A, Sugiura W, Ohmagari N, Sugiyama H. Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial. JMIR Res Protoc, 9(12):e23830, 2020.
  8. Kato T, Uemura Y, Naya M, Matsumoto N, Momose M, Hida S, Yamauchi T, Nakajima T, Suzuki E, Inoko M, Shiga T, Tamaki N. Association of coronary revascularisation after physician-referred non-invasive diagnostic imaging tests with outcomes in patients with suspected coronary artery disease: a post hoc subgroup analysis. BMJ Open, 10(9):e035111, 2020.
  9. Sugawara K, Yagi K, Uemura Y, Okumura Y, Nishida M, Aikou S, Yamashita H, Seto Y. Associations of Systemic Inflammation and Sarcopenia With Survival of Esophageal Carcinoma Patients. Ann Thorac Surg, 110(2):374-382, 2020.
  10. Ko T, Higashitani M, Uemura Y, Utsunomiya M, Yamaguchi T, Matsui A, Ozaki S, Tobita K, Kodama T, Morita H, Komuro I. Clinical Outcome and Diverse Risk Factors for Different Therapeutic Target Locations of Peripheral Artery Disease. J Atheroscler Thromb. 27(8):769-779, 2020.